Literature DB >> 954353

Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.

K Verebey, J Volavka, S J Mulé, R B Resnick.   

Abstract

The disposition of naltrexone during acute and chronic administration of 100-mg oral dose was studied in 4 subjects. Following an acute dose the mean (X) peak naltrexone plasma level was 43.6 +/- 29.9 ng/ml at 1 hr and for the major biotransformation product, beta-naltrexol, was 87.2 +/- 25.0 ng/ml at 2 hr. Twenty-four hours after the dose the X levels of naltrexone and beta-naltrexol declined to 2.1 +/- 0.47 and 17.6 +/- 5.0 ng/ml, respectively. Following chronic administration and X peak plasma levels of naltrexone and beta-naltrexol rose to 46.4 +/- 18.5 and 158.4 +/- 89.9 ng/ml at 1 hr, but by 24 hr both compounds declined to levels of the same order as in the acute state at 24 hr. Plasma levels of naltrexone and beta-naltrexol measured 24 hr after the daily doses of naltrexone throughout the study indicated that steady-state equilibrium was rapidly attained and that there was no accumulation of naltrexone and beta naltrexol in the plasma after chronic treatment on 100 mg oral doses. Biexponential kinetics were observed for naltrexone and beta-naltrexol in the first 24 hr. The half-life of naltrexone and beta-naltrexol decreased slightly from the acute to thechronic study from 10.3 +/- 3.3 to 9.7 +/- 1.1 hr and from 12.7 +/- 2.6 to 11.4 +/- 2.0 hr. The plasma levels of naltrexone declined slowly from 24 through 72 hr from 2.4 to 1.7 ng/ml, with an apparent half-life of 96 hr. The renal clearance data indicate that naltrexone is partially reabsorbed while beta naltrexol is actively secreted by the kidney. During acute and chronic naltrexone administration the mean fecal excretion was 2.1% and 3.6% while urinary excretion was 38% and 70% of the dose in a 24-hr period. Opiate antagonism to 25 mg heroin challenges was nearly complete through 48 hr after naltrexone. At 72 hr the objective responses reappeared to a greater extent than the subjective ones. Correlation coefficient (r) between naltrexone plasma levels and opiate antagonism was 0.91 and between individual half-life of naltrexone and opiate antagonism it was 0.99.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954353     DOI: 10.1002/cpt1976203315

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  47 in total

1.  Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

Authors:  Linda Olsen; Asbjørg S Christophersen; Grete Frogopsahl; Helge Waal; Jørg Mørland
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 2.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

3.  Effects of extended-release injectable naltrexone on self-injurious behavior in rhesus macaques (Macaca mulatta).

Authors:  Doty J Kempf; Kate C Baker; Margaret H Gilbert; James L Blanchard; Reginald L Dean; Daniel R Deaver; Rudolf P Bohm
Journal:  Comp Med       Date:  2012-06       Impact factor: 0.982

4.  Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.

Authors:  Evgeny Krupitsky; Edwin Zvartau; Elena Blokhina; Elena Verbitskaya; Valentina Wahlgren; Marina Tsoy-Podosenin; Natalia Bushara; Andrey Burakov; Dmitry Masalov; Tatyana Romanova; Arina Tyurina; Vladimir Palatkin; Tatyana Yaroslavtseva; Anna Pecoraro; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-19       Impact factor: 3.829

Review 5.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

6.  Mu opioid mediated discriminative-stimulus effects of tramadol: an individual subjects analysis.

Authors:  Justin C Strickland; Craig R Rush; William W Stoops
Journal:  J Exp Anal Behav       Date:  2015-02-09       Impact factor: 2.468

7.  Stimulus effects of delta(9)-THC and its interaction with naltrexone and catecholamine blockers in rats.

Authors:  T U Järbe; G C Ohlin
Journal:  Psychopharmacology (Berl)       Date:  1977-10-20       Impact factor: 4.530

Review 8.  A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.

Authors:  B J Berg; H M Pettinati; J R Volpicelli
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 9.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

10.  Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man.

Authors:  J D Veldhuis; A D Rogol; E Samojlik; N H Ertel
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.